Filtered By:
Specialty: Drugs & Pharmacology
Drug: Clopidogrel
This page shows you your search results in order of relevance. This is page number 15.
Order by Relevance | Date
Total 241 results found since Jan 2013.
Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention: A systematic review and meta-analysis
CONCLUSION: DAPT may be shortened to 3 months in patients with low ischemic risk but high bleeding risk, whereas it may be extended to >12 months in case of high ischemic and low bleeding risk. The concept of P2Y12 inhibitor monotherapy, although promising, needs to be challenged.PROSPERO REGISTRATION NO: CRD42020163719.PMID:33753284 | DOI:10.1016/j.vph.2021.106858
Source: Vascular Pharmacology - March 23, 2021 Category: Drugs & Pharmacology Authors: Georg Gelbenegger Ummahan Erari-Canyurt J ürgen Grafeneder Bernd Jilma Maciej Lesiak Anna Komosa Raffaele de Caterina Marek Postula Jolanta M Siller-Matula Source Type: research
Serum Free Triiodothyronine and the Responsiveness to Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention
ConclusionsLow FT3 was independently associated with increased risks of both low responsiveness to clopidogrel and cardiovascular events in patients undergoing elective PCI.
Source: Advances in Therapy - April 29, 2021 Category: Drugs & Pharmacology Source Type: research
Non-Persistence With Antiplatelet Medications Among Older Patients With Peripheral Arterial Disease
Conclusion: In patients with an increased probability of non-persistence, an increased attention should be paid to improvement of persistence.
Source: Frontiers in Pharmacology - May 19, 2021 Category: Drugs & Pharmacology Source Type: research
Cost-Effectiveness of Ticagrelor Compared with Clopidogrel in Patients with Acute Coronary Syndrome from Vietnamese Healthcare Payers ’ Perspective
ConclusionTicagrelor can be considered a cost-effective treatment for ACS compared with clopidogrel from a Vietnamese healthcare payers' perspective.
Source: Advances in Therapy - June 11, 2021 Category: Drugs & Pharmacology Source Type: research
Effects of Aging on Clinical Outcomes in Patients Receiving Genotype ‐Guided P2Y12 Inhibitor Selection after Percutaneous Coronary Intervention
ConclusionThis study suggests important clinical benefits ofCYP2C19 genotype-guided antiplatelet therapy after PCI in both younger and older patients.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 10, 2021 Category: Drugs & Pharmacology Authors: Brian Wood,
Craig R. Lee,
Ian R. Mulrenin,
Megan N. Gower,
Joseph S. Rossi,
Karen E. Weck,
George A. Stouffer Tags: ORIGINAL RESEARCH Source Type: research
Effects of aging on clinical outcomes in patients receiving genotype ‐guided P2Y12 inhibitor selection after percutaneous coronary intervention
ConclusionThis study suggests important clinical benefits ofCYP2C19 genotype-guided antiplatelet therapy after PCI in both younger and older patients.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 21, 2021 Category: Drugs & Pharmacology Authors: Brian Wood,
Craig R. Lee,
Ian R. Mulrenin,
Megan N. Gower,
Joseph S. Rossi,
Karen E. Weck,
George A. Stouffer Tags: TI on Advances in Cardiovascular Pharmacotherapy Source Type: research
Utility of a pharmacogenetic-driven algorithm in guiding dual antiplatelet therapy for patients undergoing coronary drug-eluting stent implantation in China
ConclusionTailored DAPT based on the PRiS could assist in improving the prognosis of patients undergoing DES implantation. Further randomized controlled trials are required to provide more evidence for PRiS-guided DAPT.
Source: European Journal of Clinical Pharmacology - October 12, 2021 Category: Drugs & Pharmacology Source Type: research
Update on Cilostazol: A Critical Review of its Antithrombotic and Cardiovascular Actions and its Clinical Applications
This article is protected by copyright. All rights reserved.PMID:34671983 | DOI:10.1002/jcph.1988
Source: The Journal of Clinical Pharmacology - October 21, 2021 Category: Drugs & Pharmacology Authors: Antonis A Manolis Theodora A Manolis Helen Melita Dimitri P Mikhailidis Antonis S Manolis Source Type: research
Comparison of Net Clinical Benefit Between Clopidogrel and Ticagrelor Following Percutaneous Coronary Intervention in Patients in China With Acute Coronary Syndrome
ConclusionIn Chinese ACS patients who underwent PCI with second-generation DESs, outpatient use of clopidogrel dual antiplatelet therapy (DAPT) was associated with reduction in NACCE and bleeding.
Source: Advances in Therapy - December 13, 2021 Category: Drugs & Pharmacology Source Type: research
Influence of Clinically Significant Genes on Antiplatelet Effect of Clopidogrel and Clinical Outcomes in Patients with Acute Coronary Syndrome and Atrial Fibrillation
Conclusion: In our study, we determined that carriers of CYP4F2 gene polymorphisms C(Val433Met)T, PEAR1 rs41273215 C#x3e;T (CT+TT) were associated with lower safety of antithrombotic therapy in patients with ACS and AF. And, the B4GALT2 rs1061781 gene polymorphism was associated with a greater risk of insufficient efficacy of the therapy. The data obtained in our study may improve the understanding of the effect of less studied genetic markers on the efficacy and safety of antithrombotic therapy in patients with ACS and AF.Pharmacology
Source: Pharmacology - January 24, 2022 Category: Drugs & Pharmacology Source Type: research
